CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    Garrigue I

    Mutations:

    Mutant Gene Virus Reference
    A4T UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D12E UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G16A UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E17A UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E17del UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    Q23K UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D24G UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    S28F UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E39D UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D40N UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E42G UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G56D UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G61D UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    L70I UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    A95V UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    V113L UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    S153P UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    N408S UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230